Seres Therapeutics, Inc. Operating Expenses
Seres Therapeutics, Inc. (MCRB) reported Operating Expenses of $22.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Seres Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $22.01M, a 11.54% decline year-over-year.
- Seres Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $21.27M, a 21.92% decline year-over-year.
- Seres Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $19.82M, a 31.28% decline year-over-year.
- Seres Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $22.83M, a 21.74% decline year-over-year.
- Seres Therapeutics, Inc. operating expenses for fiscal 2025 was $94.76M, a 21.89% decline from fiscal 2024.
- Seres Therapeutics, Inc. operating expenses for fiscal 2024 was $121.31M, a 37.82% decline from fiscal 2023.
- Seres Therapeutics, Inc. operating expenses for fiscal 2023 was $195.10M, a 8.44% increase from fiscal 2022.
- Seres Therapeutics, Inc. operating expenses for fiscal 2022 was $179.91M, a 14.09% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.01M 10-Q · filed 2026-08-05 | $43.27M 10-Q · filed 2026-08-05 | $63.09M derived: sum of 3 quarters · filed 2026-08-05 | $85.92M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $21.27M 10-Q · filed 2026-05-05 | $41.08M derived: sum of 2 quarters · filed 2026-05-05 | $63.91M derived: sum of 3 quarters · filed 2026-05-05 | $88.79M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $19.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $42.64M derived: sum of 2 quarters · filed 2026-03-12 | $67.52M derived: sum of 3 quarters · filed 2026-08-05 | $94.76M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $22.83M 10-Q · filed 2025-11-05 | $47.71M derived: sum of 2 quarters · filed 2026-08-05 | $74.94M 10-Q · filed 2025-11-05 | $103.78M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $24.88M 10-Q · filed 2026-08-05 | $52.12M 10-Q · filed 2026-08-05 | $80.95M derived: sum of 3 quarters · filed 2026-08-05 | $110.12M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $27.24M 10-Q · filed 2026-05-05 | $56.07M derived: sum of 2 quarters · filed 2026-05-05 | $85.24M derived: sum of 3 quarters · filed 2026-05-05 | $114.11M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $28.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $58.01M derived: sum of 2 quarters · filed 2026-03-12 | $86.88M derived: sum of 3 quarters · filed 2026-03-12 | $121.31M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $29.17M 10-Q · filed 2025-11-05 | $58.04M derived: sum of 2 quarters · filed 2025-11-05 | $92.48M 10-Q · filed 2025-11-05 | $129.50M derived: sum of 4 quarters · filed 2026-03-12 | ||||
| 2024-06-30 | $28.87M 10-Q · filed 2025-08-06 | $31.34M 10-Q · filed 2024-08-13 | $63.31M 10-Q · filed 2025-08-06 | $70.93M 10-Q · filed 2024-08-13 | $100.33M derived: sum of 3 quarters · filed 2026-03-12 | $144.92M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-03-31 | $34.44M 10-Q · filed 2025-05-07 | $39.59M 10-Q · filed 2024-05-08 | $71.46M derived: sum of 2 quarters · filed 2026-03-12 | $116.05M derived: sum of 3 quarters · filed 2026-03-12 | $193.00M derived: sum of 4 quarters · filed 2026-03-12 | |||
| 2023-12-31 | $37.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $81.61M derived: sum of 2 quarters · filed 2026-03-12 | $158.56M derived: sum of 3 quarters · filed 2026-03-12 | $195.10M 10-K · filed 2026-03-12 | $234.31M 10-K · filed 2024-03-05 | |||
| 2023-09-30 | $44.59M 10-Q · filed 2024-11-13 | $47.72M 10-Q · filed 2023-11-02 | $121.53M derived: sum of 2 quarters · filed 2024-11-13 | $158.07M 10-Q · filed 2024-11-13 | $194.72M 10-Q · filed 2023-11-02 | $187.16M derived: sum of 4 quarters · filed 2025-03-13 | ||
| 2023-06-30 | $76.95M 10-Q · filed 2024-08-13 | $147.00M 10-Q · filed 2024-08-13 | $142.57M derived: sum of 3 quarters · filed 2025-03-13 | $205.12M derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2023-03-31 | $70.05M 10-Q · filed 2024-05-08 | $65.62M derived: sum of 2 quarters · filed 2025-03-13 | $128.18M derived: sum of 3 quarters · filed 2025-03-13 | $192.72M derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2022-12-31 | -$4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $58.13M derived: sum of 2 quarters · filed 2025-03-13 | $122.67M derived: sum of 3 quarters · filed 2025-03-13 | $179.91M 10-K · filed 2025-03-13 | $253.62M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $62.55M 10-Q · filed 2023-11-02 | $127.09M derived: sum of 2 quarters · filed 2023-11-02 | $184.34M 10-Q · filed 2023-11-02 | $240.99M derived: sum of 4 quarters · filed 2024-03-05 | ||||
| 2022-06-30 | $64.54M 10-Q · filed 2023-08-08 | $121.78M 10-Q · filed 2023-08-08 | $178.44M derived: sum of 3 quarters · filed 2024-03-05 | $236.76M derived: sum of 4 quarters · filed 2024-03-05 | ||||
| 2022-03-31 | $57.24M 10-Q · filed 2023-05-09 | $113.90M derived: sum of 2 quarters · filed 2024-03-05 | $172.22M derived: sum of 3 quarters · filed 2024-03-05 | $225.62M derived: sum of 4 quarters · filed 2024-03-05 | ||||
| 2021-12-31 | $56.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $114.97M derived: sum of 2 quarters · filed 2024-03-05 | $168.38M derived: sum of 3 quarters · filed 2024-03-05 | $209.42M 10-K · filed 2024-03-05 | ||||
| 2021-09-30 | $58.32M 10-Q · filed 2022-11-02 | $111.72M derived: sum of 2 quarters · filed 2022-11-02 | $152.77M 10-Q · filed 2022-11-02 | $188.23M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2021-06-30 | $53.41M 10-Q · filed 2022-08-03 | $94.45M 10-Q · filed 2022-08-03 | $129.91M derived: sum of 3 quarters · filed 2023-03-07 | $161.32M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2021-03-31 | $41.04M 10-Q · filed 2022-05-04 | $76.51M derived: sum of 2 quarters · filed 2023-03-07 | $107.92M derived: sum of 3 quarters · filed 2023-03-07 | $134.51M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2020-12-31 | $35.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $66.87M derived: sum of 2 quarters · filed 2023-03-07 | $93.46M derived: sum of 3 quarters · filed 2023-03-07 | $121.34M 10-K · filed 2023-03-07 | ||||
| 2020-09-30 | $31.41M 10-Q · filed 2021-11-10 | $58.00M derived: sum of 2 quarters · filed 2021-11-10 | $85.88M 10-Q · filed 2021-11-10 | $112.70M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $26.59M 10-Q · filed 2021-08-03 | $54.47M 10-Q · filed 2021-08-03 | $81.28M derived: sum of 3 quarters · filed 2021-08-03 | $105.50M derived: sum of 4 quarters · filed 2021-08-03 | ||||
| 2020-03-31 | $27.88M 10-Q · filed 2021-05-04 | $54.70M derived: sum of 2 quarters · filed 2021-05-04 | $78.91M derived: sum of 3 quarters · filed 2021-05-04 | $102.39M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | $26.81M 10-K · filed 2020-03-02 | $51.03M derived: sum of 2 quarters · filed 2020-11-09 | $74.51M derived: sum of 3 quarters · filed 2020-11-09 | $106.38M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $24.21M 10-Q · filed 2020-11-09 | $47.69M derived: sum of 2 quarters · filed 2020-11-09 | $79.57M 10-Q · filed 2020-11-09 | $111.87M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $23.48M 10-Q · filed 2020-07-28 | $55.35M 10-Q · filed 2020-07-28 | $87.65M derived: sum of 3 quarters · filed 2020-07-28 | $118.92M derived: sum of 4 quarters · filed 2020-07-28 | ||||
| 2019-03-31 | $31.87M 10-Q · filed 2020-05-07 | $64.17M derived: sum of 2 quarters · filed 2020-05-07 | $95.44M derived: sum of 3 quarters · filed 2020-05-07 | $128.19M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $32.30M 10-K · filed 2020-03-02 | $63.57M derived: sum of 2 quarters · filed 2020-03-02 | $96.31M derived: sum of 3 quarters · filed 2020-03-02 | $128.55M 10-K · filed 2021-03-02 | ||||
| 2018-09-30 | $31.27M 10-K · filed 2020-03-02 | $64.01M derived: sum of 2 quarters · filed 2020-03-02 | $96.25M 10-Q · filed 2019-11-05 | $129.08M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $32.75M 10-K · filed 2020-03-02 | $64.98M 10-Q · filed 2019-08-06 | $97.82M derived: sum of 3 quarters · filed 2020-03-02 | $128.15M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $32.24M 10-K · filed 2020-03-02 | $65.07M derived: sum of 2 quarters · filed 2020-03-02 | $95.40M derived: sum of 3 quarters · filed 2020-03-02 | $126.83M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $32.83M 10-K · filed 2019-03-06 | $63.16M derived: sum of 2 quarters · filed 2019-03-06 | $94.59M derived: sum of 3 quarters · filed 2019-03-06 | $123.50M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $30.33M 10-K · filed 2019-03-06 | $61.76M derived: sum of 2 quarters · filed 2019-03-06 | $90.66M 10-Q · filed 2018-11-08 | $119.39M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2017-06-30 | $31.43M 10-K · filed 2019-03-06 | $60.34M 10-Q · filed 2018-08-02 | $89.06M derived: sum of 3 quarters · filed 2019-03-06 | $121.17M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2017-03-31 | $28.91M 10-K · filed 2019-03-06 | $57.63M derived: sum of 2 quarters · filed 2019-03-06 | $89.74M derived: sum of 3 quarters · filed 2019-03-06 | $120.88M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2016-12-31 | $28.73M 10-K · filed 2018-03-08 | $60.84M derived: sum of 2 quarters · filed 2018-03-08 | $91.98M derived: sum of 3 quarters · filed 2018-03-08 | $114.61M 10-K · filed 2019-03-06 | ||||
| 2016-09-30 | $32.11M 10-K · filed 2018-03-08 | $63.25M derived: sum of 2 quarters · filed 2018-03-08 | $85.90M 10-Q · filed 2017-11-08 | $105.67M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $31.14M 10-K · filed 2018-03-08 | $53.77M 10-Q · filed 2017-08-03 | $73.56M derived: sum of 3 quarters · filed 2018-03-08 | $88.12M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-03-31 | $22.63M 10-K · filed 2018-03-08 | $42.41M derived: sum of 2 quarters · filed 2018-03-08 | $56.98M derived: sum of 3 quarters · filed 2018-03-08 | $69.31M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2015-12-31 | $19.79M 10-K · filed 2017-03-16 | $34.35M derived: sum of 2 quarters · filed 2017-03-16 | $46.69M derived: sum of 3 quarters · filed 2017-03-16 | $54.86M 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | $14.56M 10-K · filed 2017-03-16 | $26.90M derived: sum of 2 quarters · filed 2017-03-16 | $35.07M 10-Q · filed 2016-11-10 | $42.28M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $12.34M 10-K · filed 2017-03-16 | $20.51M 10-Q · filed 2016-08-11 | $27.72M derived: sum of 3 quarters · filed 2017-03-16 | $31.30M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $8.17M 10-K · filed 2017-03-16 | $15.38M derived: sum of 2 quarters · filed 2017-03-16 | $18.96M derived: sum of 3 quarters · filed 2017-03-16 | $21.58M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | $7.21M 10-K · filed 2016-03-14 | $10.79M derived: sum of 2 quarters · filed 2016-03-14 | $13.41M derived: sum of 3 quarters · filed 2016-03-14 | $15.08M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $3.58M 10-K · filed 2016-03-14 | $6.20M derived: sum of 2 quarters · filed 2016-03-14 | $7.87M 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | $2.62M 10-K · filed 2016-03-14 | $4.29M 10-Q · filed 2015-08-10 | ||||||
| 2014-03-31 | $1.67M 10-K · filed 2016-03-14 | |||||||
| 2013-12-31 | $6.05M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |